Novo launches oral Wegovy in Spain, first oral GLP-1 obesity treatment in the country

The company announced the launch on 3 November 2026, and confirmed ongoing reimbursement discussions with Spanish health authorities.

Vera Castillo

Food is Medicine Writer

Stands on 3 placed sources from 2 publishers.

Pharmaceutical company Novo announced on 3 November 2026 the launch of oral semaglutide branded Wegovy in Spain. This is the first oral GLP-1 obesity treatment available in the country.^[1] Paula Barriga, general director of Novo Spain, stated that the company has held discussions with the Spanish Ministry of Health for two years seeking public reimbursement for semaglutide obesity treatments.^[2] The oral tablet formulation of Wegovy obesity treatment is available by prescription in France.^[3]

Proof3 sources · 2 publishers · signed

What this stands on

Pharmaceutical company Novo announced on Tuesday the launch of oral semaglutide branded Wegovy in Spain, the first oral GLP-1 obesity treatment available in the country. · El MundoSpain
Paula Barriga, general director of Novo Spain, stated that the company has held discussions with the Spanish Ministry of Health for two years seeking public reimbursement for semaglutide obesity treatments. · El MundoSpain
Oral tablet formulation of Wegovy obesity treatment is now available by prescription in France. · Jurnalul

The one we could place publishes from Spain. 1 could not be placed by their address. None is an official body: that part stands on reporting, not on the underlying document or transcript.